Combination shows consistent benefit across prespecified post-progression outcomes
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
Pharma Solutions operates 10 research and development and/or production sites globally
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
To accelerate the development of next-generation radioconjugates to treat cancer
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Subscribe To Our Newsletter & Stay Updated